RelieVRx—first in a new class of non-pharmacological pain treatment1-7

RelieVRx is the first comprehensive, immersive adjunctive VR treatment for chronic pain to ever be FDA-authorized.

RelieVRx promotes neuroplasticity and enables patients to build long-term skills to respond to pain.

biospsychosocial icon

Rooted in biopsychosocial pain education1

RelieVRx is a novel adjunctive pain management program rooted in evidence-based principles for the treatment of patients living with CLBP.

safety icon

A therapeutic option with fewer trade-offs1

In clinical studies, RelieVRx use did not trigger any serious AEs, with a manageable side effect profile.

at home use icon

Patient-empowered pain management1

RelieVRx empowers patients to be active in their own pain management simply and non-pharmacologically. VR treatment is self-administered over 8 weeks in the comfort of a patient's home with an average daily session of 7 minutes duration.

The RelieVRx Program

RelieVRx engages pain centers through various ways:

Mindfulness icon

Mindful Escapes

Brain icon

Pain Education

Breathing icon

Diaphragmatic Breathing

Meditation icon

Relaxation/ Interoception

Dynamic breathing

Responsive training environments enhance diaphragmatic breathing allowing patients to activate and control their parasympathetic response3

RelieVRx offers a simple user experience at every step of the journey

Doctor icon
1. At prescribing

After prescribing RelieVRx and sending the Rx to the Hub, the Hub will ship the device directly to the patient's home with easy-to-follow instructions.

VR headset icon
2. Ready to Use

RelieVRx comes ready to use out of the box with preloaded content.

Returning shipping box icon
3. Returning the device

Patients will then return the device in the original packaging using the provided prepaid return shipping label.

Stay on the cutting edge of pain treatment by registering to receive updates about RelieVRx and educational information for you and your staff.


Indication for Use

RelieVRx is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back-pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.


There are no known contraindications.


  1. RelieVRx [instructions for use]. Van Nuys, CA: AppliedVR, Inc.; 2021.
  2. Garcia LM, Birckhead BJ, Krishnamurthy P, et al. Three-month follow-up results of a double-blind, randomized placebo-controlled trial of 8-week self-administered at-home behavioral skills-based virtual reality (VR) for chronic low back pain. J Pain. 2021.
  3. Garcia LM, Birckhead BJ, Krishnamurthy P, et al. An 8-week self-administered at-home behavioral skills-based virtual reality program for chronic low back pain: double-blind, randomized, placebo-controlled trial conducted during COVID-19. J Med Internet Res. 2021;23(2):e26292. doi:10.2196/26292
  4. AppliedVR Press Release. Accessed January 18, 2022.
  5. Bak MS, Park H, Kim SK. Neural plasticity in the brain during neuropathic pain. Biomedicines. 2021;9(6):624. doi: 10.3390/biomedicines9060624
  6. Austin PD, Siddall PJ. Virtual reality for the treatment of neuropathic pain in people with spinal cord injuries: a scoping review. J Spinal Cord Med.2021;44(1):8-18. doi: 10.1080/10790268.2019.1575554
  7. Hoffman HG, Richards TL, Coda B, et al. Modulation of thermal pain-related brain activity with virtual reality: evidence from fMRI. Neuroreport. 2004;15(8):1245-1248. doi:10.1097/01.wnr.0000127826.73576.91

RelieVRx was formerly known as EaseVRx.